// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























2187 Abstracts

EVALUATION OF THE DIAGNOSTIC ALGORITHM IN PH-LIKE ALL

Helena Podgornik - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

AN ORAL, CHEMOTHERAPY-FREE REGIMEN (DASATINIB PLUS PREDNISONE) AS INDUCTION AND CONSOLIDATION FOR ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME–POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

Xueying Li - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Prednisone

PATTERNS OF MOLECULAR RESPONSE TO INDUCTION THERAPY IN ETV6-RUNX1+ ACUTE LYMPHOBLASTIC LEUKEMIA

Mariana Corrochano - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

OVER-EXPRESSION OF CRLF2 BY FLOW CYTOMETRY (FC) AND DEFINED BY RATIO B, IMPACTS ON DISEASE-FREE SURVIVAL (DFS) IN MEXICAN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL).

Emmanuel Almanza Huante - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

COST-UTILITY OF PROTOCOLS OF BFM-ALL AND UK-ALL FOR TREATMENT OF CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN IRAN

Mohammadali Ehsani - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Acute lymphoblastic leukemia

N/A

MANAGEMENT OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA IN A COUNTRY WITH LIMITED RESOURCES: A REAL LIFE MONOCENTRIC EXPERIENCE.

Mounir Ababou - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

FREQUENCY OF DISSEMINATED INTRAVASCULAR COAGULATION IN ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: A RETROSPECTIVE ANALYSIS

Hayden A. Jina - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

Asparaginase

INOTUZUMAB OZAGAMICIN IS SAFE AND EFFECTIVE IN RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA: A SINGLE ITALIAN CENTER EXPERIENCE

Chiara Sartor - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Inotuzumab ozogamicin

REAL-WORLD TREATMENT PATTERNS AMONG PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY (CAR T)

Jessica J Jalbert - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

BOSUTINIB FOR CHRONIC PHASE CHRONIC MYELOID LEUKEMIA AFTER IMATINIB FAILURE: ≥8-YEAR UPDATE OF A PHASE 1/2 STUDY

Jorge E. Cortes - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Bosutinib

CUTANEOUS HEMORRHAGE TYPES AS SUPPORTIVE FACTORS FOR PREDICTING CHRONIC IMMUNE THROMBOCYTOPENIA IN CHILDREN

Nechama Sharon - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Methadone hydrochloride

SECOND ALLOGENEIC STEM CELL TRANSPLANTATION WITH HAPLOIDENTICAL GRAFTS FOR POST-TRANSPLANT RELAPSE

Samer A. Srour - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Allopurinol

OUTCOME OF FLUDARABINE-BUSULFAN-ANTI THYMOCYTE GLOBULIN (FLU-BU-ATG) CONDITIONING REGIMEN FOR ALLOGENEIC HEMATOPIETIC STEM CELL TRANSPLANTATION

Ahmed Askar - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Cyclophosphamide

RITUXIMAB FOR THE PREVENTION OF ANEMIA POST ABO MAJOR INCOMPATIBLE ALLOGENEIC STEM CELL TRANSPLANTATION.

Maria Chiara Finazzi - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

Rituximab

THE PROGNOSTIC VALUE OF KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR–LIGAND MISMATCH IN DONOR VERSUS RECIPIENT DIRECTION ON THE OUTCOMES OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION.

Zoya Konova - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Cyclophosphamide

AN INSPIRING RESULT OF UMBILICAL CORD BLOOD TRANSPLANTATION AFTER ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR THERAPY IN CHILDREN RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA

Fang Liu - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Acute lymphoblastic leukemia

Mycophenolate mofetil

INTERPRETATION OF THE RESULTS OF ABO, RH-ANTIGENS AND ANTIBODIES DETERMINATION IN PATIENTS WITH HEMATOLOGICAL DISEASES

Irina Krobinets - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute lymphoblastic leukemia

N/A

COMPARISON OF TWO QPCR-BASED METHODS FOR MEASUREMENT OF MINIMAL RESIDUAL DISEASE IN B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA WITH THREE MAJOR FUSION TRANSCRIPTS

Ying-Jung Huang - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

CIRCULATING MICRORNAS AS MINIMAL RESIDUAL DISEASE BIOMARKERS IN PAEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA

Andrea Rzepiel - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

TARGETING NUCLEOLIN FOR IMPROVING SUSCEPTIBILITY TO CHEMOTHERAPY IN ACUTE LYMPHOBLASTIC LEUKEMIA

Yanxin Chen - European Hematology Association (EHA) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Adriamycin injection

Copyright © 2026. QuantiNova All rights reserved